Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Laureate Pharma, a biopharmaceutical development and protein production company, has entered into a current good manufacturing practice contract manufacturing agreement with Tolera Therapeutics, a biotechnology company that develops and offers targeted therapies for immune modulation and related medical needs.
Subscribe to our email newsletter
According to the agreement, Laureate will produce Tolera’s TOL101 monoclonal antibody under current good manufacturing practice (cGMP) conditions to be used in clinical trials.
John Puisis, president and CEO of Tolera, said: “We are excited to work with Laureate, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities in both clinical and commercial-grade materials can support our aggressive development and commercial plans. We look forward to our partnership with Laureate in utilizing their specialized experience in the manufacture of monoclonal antibodies.”